|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2009-10-13
|
|
pubmed:abstractText |
The aim of the current study was the investigation of the value of bevacizumab+5-fluorouracil(5-FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:CaricatoMarcoM,
pubmed-author:CoppolaRobertoR,
pubmed-author:GasparroSimonaS,
pubmed-author:RizzoSergioS,
pubmed-author:RussoAntonioA,
pubmed-author:SantiniDanieleD,
pubmed-author:SpotoChiaraC,
pubmed-author:ToniniGiuseppeG,
pubmed-author:ValeriSergioS,
pubmed-author:VendittiOlgaO,
pubmed-author:VincenziBrunoB,
pubmed-author:ZobelBruno BeomonteBB
|
|
pubmed:copyrightInfo |
Copyright (c) 2009 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4849-56
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19626652-Adult,
pubmed-meshheading:19626652-Aged,
pubmed-meshheading:19626652-Antibodies, Monoclonal,
pubmed-meshheading:19626652-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19626652-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19626652-Colorectal Neoplasms,
pubmed-meshheading:19626652-Drug Administration Schedule,
pubmed-meshheading:19626652-Drug Resistance, Neoplasm,
pubmed-meshheading:19626652-Female,
pubmed-meshheading:19626652-Fluorouracil,
pubmed-meshheading:19626652-Humans,
pubmed-meshheading:19626652-Leucovorin,
pubmed-meshheading:19626652-Male,
pubmed-meshheading:19626652-Middle Aged,
pubmed-meshheading:19626652-Retreatment
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.
|
|
pubmed:affiliation |
Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
